Takeda to invest in new facility at Grange Castle site in Ireland

Takeda has announced plans to create a new regenerative medicine facility at its site in Grange Castle in Ireland.

The company will spend EUR 25 million (GBP 22.3 million) to expand the existing footprint at Grange Castle, with the standalone modular cell therapy facility to be used to manufacture a novel stem cell therapy.

A total of 70 new jobs and an additional 70 temporary construction jobs will be created by this project, which will be supported by the Irish government through IDA Ireland. The facility is expected to be in commercial operation by 2021.

Takeda has been operating in Ireland since 1997, with Dublin chosen as the location for the firm's first active pharmaceutical ingredient facility outside of Japan in 2002. Last year, an additional EUR 40 million was pledged for the development of a standalone production facility in Grange Castle to support oncology medicine production.

Paul Keogh, plant director at the Grange Castle site, said: "We have a great team here in Ireland and are committed to continuing to put patients first through the timely manufacture and supply of high-quality products from our site."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.